- STAT+: Abivax seeks to ease safety concerns with new data, boosting sharesSafety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.STAT · 26d ago↗ source
- STAT+: FDA’s top gene therapy regulator is leaving his roleThe departure of Vijay Kumar follows a broader leadership shakeup at the FDA.STAT · 27d ago↗ source
- NEJM retracts pivotal data for Amgen's TavneosPivotal data for Amgen’s Tavneos have been retracted from the New England Journal of Medicine, creating another obstacle for the beleaguered autoimmune drug. Two academic authors requested the re…Endpoints · 27d ago↗ source